The Kobilka Institute of Innovative Drug Discovery (KIIDD) and the Warshel Institute for Computational Biology were established at The Chinese University of Hong Kong (Shenzhen) on April 10, 2017. It is named after Professor Brian Kobilka, one of the Nobel Laureates in Chemistry, 2012. Together with the third Nobel Institute, the Ciechanover Institute of Precision and Regenerative Medicine, KIIDD and the Warshel Institute form the major research team at the School of Life and Health Sciences (LHS) at the university.

As the name suggests, KIIDD aims to carry out cutting-edge studies in G-protein coupled receptors (GPCRs) as well as to discover new drugs associated with the GPCRs resolved on site. To accomplish this goal, KIIDD has recruited scientists with a broad range of expertise to construct a vibrant environment where close collaboration among research groups is possible. In addition, the institute serves as a center for cryo-EM studies at Shenzhen. With regular training in cryo-EM operation and structure determination, KIIDD trains the young generation for modern drug discovery. Currently, the research carried out at KIIDD includes determining structures of GPCRs and other transmembrane proteins, as well as revealing their functions in the human body and searching for drugs with virtual screening. Finally, to further fulfil KIIDD's mission in drug development, we also collaborate closely with researchers from the Warshel Institute, from the Ciechanover Institute, as well as with doctors from local hospitals.